rolipram has been researched along with Disease Models, Animal in 138 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rolipram attenuated cognitive decline as well as anxiety- and depression-like behaviors." | 8.31 | Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling. ( Cong, YF; Hou, XQ; Liu, D; Liu, FW; Shen, XR; Song, SS; Xu, L; Zhang, HT, 2023) |
| "To evaluate the effects of rolipram, a phosphodiesterase 4 enzyme inhibitor, on Escherichia coli-induced renal oxidative damage in an acute pyelonephritis (PYN) rat model." | 7.74 | Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats. ( Aslantaş, O; Aydin, M; Celik, S; Erdoğan, S; Görür, S; Hakverdi, S; Namik Kiper, A; Ocak, S, 2008) |
| "The purpose of this study was to evaluate the efficacy of rolipram, a phosphodiesterase (PDE) 4 inhibitor, in a mouse model of dermatitis induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB)." | 7.73 | Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. ( Harada, D; Manabe, H; Takashima, Y; Tsukumo, Y, 2006) |
| "In lungs from nonventilated, circulation-arrested donors, reperfusion with rolipram reduces the ischemia-reperfusion injury that may be due to intracellular cyclic adenosine monophosphate." | 7.70 | Reduced ischemia-reperfusion injury with rolipram in rat cadaver lung donors: effect of cyclic adenosine monophosphate. ( Becker, RM; Bleiweis, MS; Egan, TM; Hoffmann, SC; Jones, DR, 1999) |
| "Rolipram has been shown to relief inflammation and BBB damage in a variety of neurological disorders." | 5.39 | The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis. ( Brede, M; Göb, E; Heydenreich, N; Kleinschnitz, C; Kraft, P; Meuth, SG; Schwarz, T, 2013) |
| ", acutely restored capillary perfusion in a bell-shaped dose-response effect with 1 mg/kg being the lowest most efficacious dose." | 5.39 | Rolipram improves renal perfusion and function during sepsis in the mouse. ( Gokden, N; Holthoff, JH; Mayeux, PR; Patil, NK; Wang, Z, 2013) |
| "Acute pancreatitis was induced in rats by subcutaneous injections of 20 microg Cer per kilogram body weight at hourly intervals, and the animals were killed at 2, 4, or 9 hours after the first injection." | 5.36 | Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats. ( Calvo, JJ; Mangas, A; Pérez, N; Sánchez-Bernal, C; Sánchez-Yagüe, J; Sardina, JL; Sarmiento, N, 2010) |
| "Rolipram was administered at a dose of 0." | 5.35 | Improved sensorimotor function by rolipram following focal cerebral ischemia in rats. ( Hätinen, S; Jolkkonen, J; Sairanen, M; Sirviö, J, 2008) |
| "Roflumilast did not inhibit serotonin-induced bronchoconstriction 4." | 5.33 | Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. ( Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L, 2006) |
| "Rolipram attenuated cognitive decline as well as anxiety- and depression-like behaviors." | 4.31 | Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling. ( Cong, YF; Hou, XQ; Liu, D; Liu, FW; Shen, XR; Song, SS; Xu, L; Zhang, HT, 2023) |
| "Specific inhibition of PDE4 by rolipram and apremilast had potent antifibrotic effects in bleomycin-induced skin fibrosis models, in the topoisomerase I mouse model and in murine sclerodermatous chronic graft-versus-host disease." | 3.85 | Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. ( Bergmann, C; Beyer, C; Distler, JHW; Kittan, N; Maier, C; Ramming, A; Schett, G; Weinkam, R, 2017) |
| " In the present study, animals exposed to the chronic unpredictable stress (CUS), a rodent model of depression, exhibited elevated corticosterone, depressive-like behavior, memory deficits, accompanied with decreased cAMP-PKA-CREB and cAMP-ERK1/2-CREB signaling and neuroplasticity." | 3.81 | Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice. ( Li, YF; Liu, YQ; O'Donnell, JM; Wang, ZZ; Wilson, SP; Xu, Y; Yang, WX; Zhang, HT; Zhang, Y; Zhang, YZ; Zhao, N, 2015) |
| "We induced polymicrobial sepsis using the colon ascendens stent peritonitis (CASP) model in which we performed macrohemodynamic and microhemodynamic monitoring with and without systemic intravenous application of different doses of PD-4-I rolipram in Sprague-Dawley rats over 26 h." | 3.80 | Phosphodiesterase 4 inhibition dose dependently stabilizes microvascular barrier functions and microcirculation in a rodent model of polymicrobial sepsis. ( Baar, W; Flemming, S; Germer, CT; Meir, M; Roewer, N; Schick, MA; Schlegel, N; Wollborn, J; Wunder, C, 2014) |
| "We analyzed the time to death in Mycobacterium tuberculosis-infected mice receiving type 4 PDE-Is (rolipram and cilomilast) and the impact on bacterial burden, time to clearance, and relapse when types 3 and 5 PDE-Is (cilostazol and sildenafil, respectively) and rolipram were added to the standard treatment." | 3.79 | Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. ( Ammerman, NC; Bishai, WR; Maiga, M; Maiga, MC; Murphy, R; Polis, M; Siddiqui, S; Tounkara, A, 2013) |
| " Therefore, we were interested in investigating its selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs) in vitro, and its effects on ovalbumin-induced airway hyperresponsiveness in vivo, and clarifying its potential for treating asthma and chronic obstructive pulmonary disease (COPD)." | 3.77 | Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. ( Chen, CM; Han, CY; Hsu, HT; Ko, WC; Wang, KH; Yang, YL, 2011) |
| " We assessed the anti-inflammatory effects of a novel PDE4 inhibitor, apremilast, in human synovial cells from rheumatoid arthritis (RA) patients, as well as two murine models of arthritis." | 3.76 | Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. ( Andrews, M; Brennan, FM; Feldmann, M; Inglis, JJ; McCann, FE; Palfreeman, AC; Perocheau, DP; Schafer, P; Williams, RO, 2010) |
| " This study was designed to investigate the efficacy of the type 4 PDE inhibitor rolipram on acute pancreatitis in rats." | 3.75 | The selective inhibition of type IV phosphodiesterase attenuates the severity of the acute pancreatitis in rats. ( Berberoglu, U; Gülben, K; İrkin, F; Mersin, H; Öngürü, Ö; Özdemir, H, 2009) |
| "To evaluate the effects of rolipram, a phosphodiesterase 4 enzyme inhibitor, on Escherichia coli-induced renal oxidative damage in an acute pyelonephritis (PYN) rat model." | 3.74 | Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats. ( Aslantaş, O; Aydin, M; Celik, S; Erdoğan, S; Görür, S; Hakverdi, S; Namik Kiper, A; Ocak, S, 2008) |
| " We compared the effect of rolipram, a selective PDE4 inhibitor, with steroids on the clinical course of experimental colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS)." | 3.73 | Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. ( Guarner, F; Malagelada, JR; Medina, C; Mourelle, M; Salas, A; Videla, S; Vilaseca, J, 2006) |
| "The purpose of this study was to evaluate the efficacy of rolipram, a phosphodiesterase (PDE) 4 inhibitor, in a mouse model of dermatitis induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB)." | 3.73 | Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. ( Harada, D; Manabe, H; Takashima, Y; Tsukumo, Y, 2006) |
| "The indirect DA agonist amphetamine has been used to model the auditory sensory processing deficits in schizophrenia." | 3.72 | Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. ( Abel, T; Kanes, SJ; Maxwell, CR; Siegel, SJ, 2004) |
| "Using a rat model of lipopolysaccharide (LPS)-induced pulmonary inflammation, the antiinflammatory activity of SB 207499 was evaluated and compared to that of the prototypic type-4 phosphodiesterase (PDE4) inhibitor, rolipram." | 3.71 | Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. ( Chapman, R; Fine, J; Jones, H; Kreutner, W; Kung, TT; Minnicozzi, M; Spond, J, 2001) |
| "In lungs from nonventilated, circulation-arrested donors, reperfusion with rolipram reduces the ischemia-reperfusion injury that may be due to intracellular cyclic adenosine monophosphate." | 3.70 | Reduced ischemia-reperfusion injury with rolipram in rat cadaver lung donors: effect of cyclic adenosine monophosphate. ( Becker, RM; Bleiweis, MS; Egan, TM; Hoffmann, SC; Jones, DR, 1999) |
| "Rolipram is effective both in prevention and treatment of experimental crescentic glomerulonephritis." | 3.70 | Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. ( Agarwal, S; Karkar, AM; Morel, D; Pusey, CD; Smith, J; Tam, FW; Thompson, EM, 2000) |
| "A new guinea pig model of allergic asthma was used to investigate the effects of low doses of the phosphodiesterase inhibitors, rolipram (phosphodiesterase IV selective), ORG 20241 (N-hydroxy-4-(3,4-dimethoxyphenyl)-thiazole-2-carboximidamide; dual phosphodiesterase III/IV inhibitor with some selectivity for the phosphodiesterase IV isoenzyme), and of theophylline (non-selective) on allergen-induced early and late phase asthmatic reactions, bronchial hyperreactivity to histamine inhalation, and airway inflammation." | 3.69 | Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. ( Meurs, H; Olymulder, CG; Santing, RE; Van der Molen, K; Zaagsma, J, 1995) |
| "Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases." | 2.66 | Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19? ( Pinho, V; Sousa, LP; Teixeira, MM, 2020) |
| "Bacteremia-induced sepsis is a leading cause of mortality in intensive care units." | 1.62 | Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice. ( Alalaiwe, A; Dai, YS; Fang, JY; Liao, CC; Liu, FC; Yang, SC; Yu, HP, 2021) |
| "Rolipram has been shown to play a neuroprotective role in some central nervous system (CNS) diseases." | 1.62 | The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway. ( Dong, XL; Wang, YH; Xu, J; Zhang, N, 2021) |
| "Cognitive impairment often occurs in Parkinson's disease (PD), but the mechanism of onset remains unknown." | 1.46 | Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. ( Ishii, T; Kinoshita, KI; Muroi, Y; Unno, T, 2017) |
| " Chronic administration of rolipram prevented the memory impairments induced by Aβ25-35, as assessed using the passive avoidance test and the Morris water maze test." | 1.43 | Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by Aβ25-35 in rats. ( Cheng, Y; Gan, D; Guo, H; Li, Y; Wang, C; Wu, J; Xu, J; Zhuo, Y; Zou, Z, 2016) |
| "Acute pulmonary inflammation is characterized by migration of polymorphonuclear neutrophils (PMNs) into the different compartments of the lung, passing an endothelial and epithelial barrier." | 1.42 | The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation. ( Bury, A; Konrad, FM; Ngamsri, KC; Reutershan, J; Schick, MA, 2015) |
| "Rolipram has been shown to relief inflammation and BBB damage in a variety of neurological disorders." | 1.39 | The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis. ( Brede, M; Göb, E; Heydenreich, N; Kleinschnitz, C; Kraft, P; Meuth, SG; Schwarz, T, 2013) |
| ", acutely restored capillary perfusion in a bell-shaped dose-response effect with 1 mg/kg being the lowest most efficacious dose." | 1.39 | Rolipram improves renal perfusion and function during sepsis in the mouse. ( Gokden, N; Holthoff, JH; Mayeux, PR; Patil, NK; Wang, Z, 2013) |
| "Chorioamnionitis is implicated in the pathophysiology of bronchopulmonary disease, and the associated inflammatory response is responsible for adverse effects on alveolar development." | 1.38 | Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits. ( Branger, B; Caillon, J; Gras-Leguen, C; Homer, L; Jacqueline, C; Jarreau, PH; Joram, N; Launay, E; Méhats, C; Moyon, T; Potel, G; Roze, JC, 2012) |
| "Rolipram induces an increase in pERK expression in these interneurons." | 1.38 | Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition. ( Anzilotti, S; Bernardi, G; Colucci D'Amato, L; Dato, C; Fusco, FR; Giampà, C; Laurenti, D; Leuti, A; Melone, MA; Perrone, L, 2012) |
| "Alcohol dependence is a complex psychiatric disorder demanding development of novel pharmacotherapies." | 1.38 | The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats. ( Lawrence, AJ; Liang, JH; Liu, Q; Qin, WJ; Wang, WP; Wen, RT; Zhang, HT; Zhang, M, 2012) |
| "Rolipram has antipsychotic properties." | 1.38 | PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis. ( Manahan-Vaughan, D; Wiescholleck, V, 2012) |
| " All these were reversed by chronic administration of rolipram (0." | 1.36 | Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. ( Cheng, YF; Huang, Y; Li, YF; Lin, HB; Wang, C; Xu, JP; Zhang, HT, 2010) |
| "Rolipram treatment significantly increased the number of motoneurons that regenerated axons across the repair site at 1 and 2 weeks, and increased the number of sensory neurons that regenerated axons across the repair site at 2 weeks." | 1.36 | Rolipram-induced elevation of cAMP or chondroitinase ABC breakdown of inhibitory proteoglycans in the extracellular matrix promotes peripheral nerve regeneration. ( Brushart, T; Furey, M; Gordon, T; Ladak, A; Tyreman, N; Udina, E, 2010) |
| "The affinities of genistein on phosphodiesterase (PDE)1-4 and cause of gastrointestinal adverse effects of genistein remain unclear." | 1.36 | Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects. ( Chen, CM; Han, CY; Ko, WC; Lai, CY; Lai, YH; Lin, LH; Shih, CH, 2010) |
| "Acute pancreatitis was induced in rats by subcutaneous injections of 20 microg Cer per kilogram body weight at hourly intervals, and the animals were killed at 2, 4, or 9 hours after the first injection." | 1.36 | Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats. ( Calvo, JJ; Mangas, A; Pérez, N; Sánchez-Bernal, C; Sánchez-Yagüe, J; Sardina, JL; Sarmiento, N, 2010) |
| " Since theophylline has two modes of action, in the present study we tested whether chronic administration of pentoxifylline, a non-selective phosphodiesterase inhibitor, rolipram, a phosphodiesterase-4 specific inhibitor, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), an adenosine A1 receptor antagonist, would induce recovery similar to that induced by theophylline in male Sprague-Dawley rats following a left C2 spinal cord lesion." | 1.35 | Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats. ( Goshgarian, HG; Kajana, S, 2008) |
| "Rolipram was effective in increasing significantly the levels of activated CREB and of BDNF the striatal spiny neurons, which might account for the beneficial effects observed in this model." | 1.35 | Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. ( Bernardi, G; DeMarch, Z; Fusco, FR; Giampà, C; Patassini, S, 2008) |
| "Rolipram was effective in inhibiting angiogenesis as assessed by hemoglobin content and VEGF levels in subcutaneous implants (about 40% with both doses) but failed to exert this activity in intraperitoneal implants." | 1.35 | Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. ( Andrade, SP; Araújo, FA; Ferreira, MA; Mendes, JB; Moura, SA; Rocha, MA, 2009) |
| "Rolipram was administered at a dose of 0." | 1.35 | Improved sensorimotor function by rolipram following focal cerebral ischemia in rats. ( Hätinen, S; Jolkkonen, J; Sairanen, M; Sirviö, J, 2008) |
| "Rolipram (0." | 1.35 | Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats. ( Hou, YH; Pan, JB; Zhang, GJ, 2009) |
| "Rolipram has a pharmacologic profile similar to that of the atypical antipsychotics and has low extrapyramidal symptom liability." | 1.34 | Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. ( Chapin, DS; Martin, AN; McCarthy, SA; Siuciak, JA, 2007) |
| "Using Lewis rats with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, we recently found a decrease in cannabinoid CB1 receptors mainly circumscribed to the basal ganglia, which could be related to the motor disturbances characteristic of these rats." | 1.33 | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. ( Cabranes, A; de Lago, E; Di Marzo, V; Fernández-Ruiz, J; Fezza, F; García-Merino, A; Mestre, L; Ramos, JA; Sánchez, A; Valenti, M; Venderova, K, 2005) |
| "Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS)." | 1.33 | Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. ( Arriaga, A; Ballester, S; García-Merino, A; González, P; Puerta, C; Sánchez, AJ, 2005) |
| "Roflumilast did not inhibit serotonin-induced bronchoconstriction 4." | 1.33 | Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. ( Beume, R; Bundschuh, DS; Marx, D; Wohlsen, A; Wollin, L, 2006) |
| " Multiple day dosing also improved activity." | 1.31 | Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. ( Egging, EA; Gullikson, GW; Hammerbeck, DM; Hupperts, AM; Johnson, DD; McGurran, SM; Radziszewski, PL, 2000) |
| "Rolipram (3 mg/kg) was administered by oral gavage from day 10 to 14 after disease induction." | 1.31 | Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. ( Cunha, FQ; Francischi, JN; Poole, S; Tafuri, WL; Teixeira, MM; Yokoro, CM, 2000) |
| "Bacterial meningitis is a disease worsened by neutrophil-induced damage in the subarachnoid space." | 1.30 | Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. ( Buster, BL; Linden, J; Scheld, WM; Sullivan, GW, 1999) |
| "Pretreatment with rolipram also attenuated increases in serum tumor necrosis factor alpha (TNFalpha) levels induced by LPS and zymosan treatment, measured after 2." | 1.30 | Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. ( Hellewell, PG; Miotla, JM; Teixeira, MM, 1998) |
| ") did not bronchodilate but caused a parallel 7 fold rightward shift in the histamine dose-response curve." | 1.29 | Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. ( Gozzard, N; Higgs, G; Holbrook, M; Hughes, B; James, T, 1996) |
| "4." | 1.29 | The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. ( Alexander, R; Allen, R; Blease, K; Bloxham, D; Boyd, E; Catterall, C; Eaton, M; Gozzard, N; Head, J; Higgs, G; Holbrook, M; Howat, D; Hughes, B; Hughes, P; James, T; Kingaby, R; Lisle, H; Lumb, S; Merriman, M; Owens, R; Perry, M; Russell, A; Smith, B; Wales, M; Warrellow, G, 1996) |
| "Pretreatment with rolipram (30 mumol/kg) and Org 20421 (30 mumol/kg) abolished the eosinophilia and neutrophilia evoked by ovalbumin." | 1.29 | Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats. ( Barnes, PJ; Chung, KF; Elwood, W; Giembycz, MA; Sun, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.72) | 18.7374 |
| 1990's | 14 (10.14) | 18.2507 |
| 2000's | 58 (42.03) | 29.6817 |
| 2010's | 52 (37.68) | 24.3611 |
| 2020's | 13 (9.42) | 2.80 |
| Authors | Studies |
|---|---|
| Cottam, HB | 1 |
| Shih, H | 1 |
| Tehrani, LR | 1 |
| Wasson, DB | 1 |
| Carson, DA | 1 |
| Andrés, JI | 1 |
| Alonso, JM | 1 |
| Díaz, A | 1 |
| Fernández, J | 1 |
| Iturrino, L | 1 |
| Martínez, P | 1 |
| Matesanz, E | 1 |
| Freyne, EJ | 1 |
| Deroose, F | 1 |
| Boeckx, G | 1 |
| Petit, D | 1 |
| Diels, G | 1 |
| Megens, A | 1 |
| Somers, M | 1 |
| Van Wauwe, J | 1 |
| Stoppie, P | 1 |
| Cools, M | 1 |
| De Clerck, F | 1 |
| Peeters, D | 1 |
| de Chaffoy, D | 1 |
| Kato, Y | 1 |
| Kawasaki, M | 1 |
| Nigo, T | 1 |
| Nakamura, S | 1 |
| Fusano, A | 1 |
| Teranishi, Y | 1 |
| Ito, MN | 1 |
| Sumiyoshi, T | 1 |
| Song, G | 1 |
| Zhu, X | 1 |
| Li, J | 1 |
| Hu, D | 1 |
| Zhao, D | 1 |
| Liao, Y | 1 |
| Lin, J | 1 |
| Zhang, LH | 1 |
| Cui, ZN | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Czopek, A | 1 |
| Bucki, A | 2 |
| Kołaczkowski, M | 1 |
| Zagórska, A | 1 |
| Drop, M | 1 |
| Pawłowski, M | 2 |
| Siwek, A | 1 |
| Głuch-Lutwin, M | 1 |
| Pękala, E | 1 |
| Chrzanowska, A | 1 |
| Struga, M | 1 |
| Partyka, A | 1 |
| Wesołowska, A | 1 |
| Ručilová, V | 1 |
| Świerczek, A | 1 |
| Vanda, D | 1 |
| Funk, P | 1 |
| Lemrová, B | 1 |
| Gawalska, A | 1 |
| Nowak, B | 1 |
| Zadrożna, M | 1 |
| Pociecha, K | 1 |
| Soural, M | 1 |
| Wyska, E | 1 |
| Chłoń-Rzepa, G | 2 |
| Zajdel, P | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Dong, XL | 1 |
| Wang, YH | 1 |
| Xu, J | 2 |
| Zhang, N | 1 |
| Megat, S | 1 |
| Hugel, S | 1 |
| Journée, SH | 1 |
| Bohren, Y | 1 |
| Lacaud, A | 1 |
| Lelièvre, V | 1 |
| Doridot, S | 1 |
| Villa, P | 1 |
| Bourguignon, JJ | 1 |
| Salvat, E | 1 |
| Schlichter, R | 1 |
| Freund-Mercier, MJ | 1 |
| Yalcin, I | 1 |
| Barrot, M | 1 |
| Macks, C | 1 |
| Jeong, D | 1 |
| Lee, JS | 2 |
| Hagihara, H | 3 |
| Shoji, H | 3 |
| Kuroiwa, M | 3 |
| Graef, IA | 3 |
| Crabtree, GR | 3 |
| Nishi, A | 3 |
| Miyakawa, T | 3 |
| Costa, WC | 1 |
| Beltrami, VA | 1 |
| Campolina-Silva, GH | 1 |
| Queiroz-Junior, CM | 1 |
| Florentino, RM | 1 |
| Machado, JR | 1 |
| Martins, DG | 1 |
| Gonçalves, WA | 1 |
| Barroso, LC | 1 |
| Freitas, KM | 1 |
| de Souza-Neto, FP | 1 |
| Félix, FB | 1 |
| da Silva, RF | 1 |
| Oliveira, CA | 1 |
| Câmara, NOS | 1 |
| Rachid, MA | 1 |
| Teixeira, MM | 5 |
| Rezende, BM | 1 |
| Pinho, V | 2 |
| Cong, YF | 1 |
| Liu, FW | 1 |
| Xu, L | 1 |
| Song, SS | 1 |
| Shen, XR | 1 |
| Liu, D | 1 |
| Hou, XQ | 1 |
| Zhang, HT | 5 |
| Ji, J | 1 |
| Liu, Z | 2 |
| Hong, X | 1 |
| Gao, J | 1 |
| Liu, J | 3 |
| Sousa, LP | 1 |
| McDonough, W | 1 |
| Aragon, IV | 1 |
| Rich, J | 1 |
| Murphy, JM | 1 |
| Abou Saleh, L | 1 |
| Boyd, A | 1 |
| Koloteva, A | 1 |
| Richter, W | 1 |
| Liao, CC | 1 |
| Yu, HP | 1 |
| Yang, SC | 1 |
| Alalaiwe, A | 1 |
| Dai, YS | 1 |
| Liu, FC | 1 |
| Fang, JY | 1 |
| Kim, NS | 1 |
| Wen, Z | 1 |
| Zhou, Y | 2 |
| Guo, Z | 1 |
| Xu, C | 1 |
| Lin, YT | 1 |
| Yoon, KJ | 1 |
| Park, J | 1 |
| Cho, M | 1 |
| Kim, M | 1 |
| Wang, X | 2 |
| Yu, H | 2 |
| Sakamuru, S | 1 |
| Christian, KM | 1 |
| Hsu, KS | 1 |
| Xia, M | 1 |
| Ross, CA | 1 |
| Margolis, RL | 1 |
| Lu, XY | 1 |
| Song, H | 1 |
| Ming, GL | 1 |
| Namvar, S | 1 |
| Fathollahi, Y | 1 |
| Javan, M | 1 |
| Zeraati, M | 1 |
| Mohammad-Zadeh, M | 1 |
| Shojaei, A | 1 |
| Mirnajafi-Zadeh, J | 1 |
| Kinoshita, KI | 1 |
| Muroi, Y | 1 |
| Unno, T | 1 |
| Ishii, T | 1 |
| Avila, DV | 2 |
| Myers, SA | 1 |
| Zhang, J | 2 |
| Kharebava, G | 1 |
| McClain, CJ | 2 |
| Kim, HY | 1 |
| Whittemore, SR | 1 |
| Gobejishvili, L | 2 |
| Barve, S | 2 |
| Ryan, S | 1 |
| Li, C | 1 |
| Menigoz, A | 1 |
| Hazra, R | 1 |
| Dabrowska, J | 1 |
| Ehrlich, D | 1 |
| Gordon, K | 1 |
| Rainnie, DG | 1 |
| Watremez, W | 1 |
| Jackson, J | 1 |
| Almari, B | 1 |
| McLean, SL | 1 |
| Grayson, B | 1 |
| Neill, JC | 1 |
| Fischer, N | 1 |
| Allouche, A | 1 |
| Koziel, V | 1 |
| Pillot, T | 1 |
| Harte, MK | 1 |
| Linhares, BL | 1 |
| Nascimento, NRF | 1 |
| Gonzaga-Silva, LF | 1 |
| Santos, CF | 1 |
| Moraes, MO | 1 |
| Marinho, LB | 1 |
| Silva, APG | 1 |
| Fonteles, MC | 1 |
| Reges, R | 1 |
| Goto, Y | 1 |
| Hiramatsu, Y | 1 |
| Ageyama, N | 1 |
| Sato, S | 1 |
| Mathis, BJ | 1 |
| Kitazawa, S | 1 |
| Matsubara, M | 1 |
| Sakamoto, H | 1 |
| Sato, Y | 3 |
| Yin, Y | 1 |
| Sun, W | 1 |
| Li, Z | 1 |
| Zhang, B | 1 |
| Cui, H | 1 |
| Deng, L | 1 |
| Xie, P | 1 |
| Xiang, J | 1 |
| Zou, J | 1 |
| Kraft, P | 1 |
| Schwarz, T | 1 |
| Göb, E | 1 |
| Heydenreich, N | 1 |
| Brede, M | 1 |
| Meuth, SG | 1 |
| Kleinschnitz, C | 1 |
| Maiga, M | 1 |
| Ammerman, NC | 1 |
| Maiga, MC | 1 |
| Tounkara, A | 1 |
| Siddiqui, S | 1 |
| Polis, M | 1 |
| Murphy, R | 1 |
| Bishai, WR | 1 |
| Holthoff, JH | 1 |
| Wang, Z | 1 |
| Patil, NK | 1 |
| Gokden, N | 1 |
| Mayeux, PR | 1 |
| Flemming, S | 1 |
| Schlegel, N | 1 |
| Wunder, C | 1 |
| Meir, M | 1 |
| Baar, W | 1 |
| Wollborn, J | 1 |
| Roewer, N | 1 |
| Germer, CT | 1 |
| Schick, MA | 2 |
| Grosso, MJ | 1 |
| Matheus, V | 1 |
| Clark, M | 2 |
| van Rooijen, N | 2 |
| Iannotti, CA | 2 |
| Steinmetz, MP | 2 |
| Totani, L | 1 |
| Piccoli, A | 1 |
| Dell'Elba, G | 1 |
| Concetta, A | 1 |
| Di Santo, A | 1 |
| Martelli, N | 1 |
| Federico, L | 1 |
| Pamuklar, Z | 1 |
| Smyth, SS | 1 |
| Evangelista, V | 1 |
| Yeo, CD | 1 |
| Kim, JW | 1 |
| Ha, JH | 1 |
| Kim, SJ | 1 |
| Lee, SH | 1 |
| Kim, IK | 1 |
| Kim, YK | 1 |
| Zygmunt, M | 1 |
| Sapa, J | 1 |
| Konrad, FM | 1 |
| Bury, A | 1 |
| Ngamsri, KC | 1 |
| Reutershan, J | 1 |
| Callaghan, CK | 1 |
| O'Mara, SM | 1 |
| Wang, ZZ | 1 |
| Yang, WX | 1 |
| Zhang, Y | 1 |
| Zhao, N | 1 |
| Zhang, YZ | 1 |
| Liu, YQ | 1 |
| Xu, Y | 1 |
| Wilson, SP | 1 |
| O'Donnell, JM | 1 |
| Li, YF | 2 |
| Jabaris, SS | 1 |
| Sumathy, H | 1 |
| Girish, R | 1 |
| Narayanan, S | 1 |
| Sugumar, M | 1 |
| Saravana Babu, C | 1 |
| Thanikachalam, S | 1 |
| Thanikachalam, M | 1 |
| Park, K | 1 |
| Choi, JS | 1 |
| Nam, YJ | 1 |
| Han, JH | 1 |
| Byun, HD | 1 |
| Song, MJ | 1 |
| Oh, JS | 1 |
| Kim, SG | 1 |
| Choi, Y | 1 |
| Vickers, SP | 1 |
| Hackett, D | 1 |
| Murray, F | 1 |
| Hutson, PH | 1 |
| Heal, DJ | 1 |
| Myeku, N | 1 |
| Clelland, CL | 1 |
| Emrani, S | 1 |
| Kukushkin, NV | 1 |
| Yu, WH | 1 |
| Goldberg, AL | 1 |
| Duff, KE | 1 |
| Wan, D | 1 |
| Wang, K | 1 |
| Hou, Y | 1 |
| Hou, R | 1 |
| Ye, X | 1 |
| Zhuo, Y | 1 |
| Guo, H | 1 |
| Cheng, Y | 1 |
| Wang, C | 4 |
| Wu, J | 1 |
| Zou, Z | 1 |
| Gan, D | 1 |
| Li, Y | 1 |
| Barker, DF | 1 |
| Dong, T | 1 |
| Zhi, L | 1 |
| Bhayana, B | 1 |
| Wu, MX | 1 |
| Zhou, ZZ | 1 |
| Cheng, YF | 3 |
| Zou, ZQ | 1 |
| Ge, BC | 1 |
| Huang, C | 1 |
| Wang, HT | 1 |
| Yang, XM | 2 |
| Xu, JP | 3 |
| Maier, C | 1 |
| Ramming, A | 1 |
| Bergmann, C | 1 |
| Weinkam, R | 1 |
| Kittan, N | 1 |
| Schett, G | 1 |
| Distler, JHW | 1 |
| Beyer, C | 1 |
| Harada, D | 2 |
| Ikeda, Y | 1 |
| Nosaka, Y | 1 |
| Kobayashi, K | 1 |
| Manabe, H | 3 |
| Görür, S | 1 |
| Celik, S | 1 |
| Hakverdi, S | 1 |
| Aslantaş, O | 1 |
| Erdoğan, S | 1 |
| Aydin, M | 1 |
| Ocak, S | 1 |
| Namik Kiper, A | 1 |
| Dong, CJ | 1 |
| Guo, Y | 1 |
| Agey, P | 1 |
| Wheeler, L | 1 |
| Hare, WA | 1 |
| de Lima, MN | 1 |
| Presti-Torres, J | 1 |
| Garcia, VA | 1 |
| Guimarães, MR | 1 |
| Scalco, FS | 1 |
| Roesler, R | 1 |
| Schröder, N | 1 |
| Paintlia, AS | 1 |
| Paintlia, MK | 1 |
| Singh, I | 1 |
| Skoff, RB | 1 |
| Singh, AK | 1 |
| Kelly, MP | 1 |
| Stein, JM | 1 |
| Vecsey, CG | 1 |
| Favilla, C | 1 |
| Yang, X | 1 |
| Bizily, SF | 1 |
| Esposito, MF | 1 |
| Wand, G | 1 |
| Kanes, SJ | 2 |
| Abel, T | 2 |
| Hätinen, S | 1 |
| Sairanen, M | 1 |
| Sirviö, J | 1 |
| Jolkkonen, J | 1 |
| Mersin, H | 1 |
| İrkin, F | 1 |
| Berberoglu, U | 1 |
| Gülben, K | 1 |
| Özdemir, H | 1 |
| Öngürü, Ö | 1 |
| Giampà, C | 4 |
| Middei, S | 1 |
| Patassini, S | 3 |
| Borreca, A | 1 |
| Marullo, F | 1 |
| Laurenti, D | 2 |
| Bernardi, G | 4 |
| Ammassari-Teule, M | 1 |
| Fusco, FR | 4 |
| Dai, H | 1 |
| MacArthur, L | 1 |
| McAtee, M | 1 |
| Hockenbury, N | 1 |
| Tidwell, JL | 1 |
| McHugh, B | 1 |
| Mansfield, K | 1 |
| Finn, T | 1 |
| Hamers, FP | 1 |
| Bregman, BS | 1 |
| Koopmans, GC | 1 |
| Deumens, R | 1 |
| Buss, A | 1 |
| Geoghegan, L | 1 |
| Myint, AM | 1 |
| Honig, WH | 1 |
| Kern, N | 1 |
| Joosten, EA | 1 |
| Noth, J | 1 |
| Brook, GA | 1 |
| Dastidar, SG | 1 |
| Ray, A | 1 |
| Shirumalla, R | 1 |
| Rajagopal, D | 1 |
| Chaudhary, S | 1 |
| Nanda, K | 1 |
| Sharma, P | 1 |
| Seth, MK | 1 |
| Balachandran, S | 1 |
| Gupta, N | 1 |
| Palle, V | 1 |
| Kajana, S | 2 |
| Goshgarian, HG | 2 |
| Pruniaux, MP | 2 |
| Lagente, V | 1 |
| Ouaged, M | 1 |
| Bertin, B | 1 |
| Moreau, F | 1 |
| Julien-Larose, C | 1 |
| Rocher, MN | 1 |
| Leportier, C | 1 |
| Martin, B | 1 |
| Bouget, A | 1 |
| Dubuit, JP | 1 |
| Burnouf, C | 1 |
| Doherty, AM | 1 |
| Bertrand, CP | 1 |
| Mendes, JB | 1 |
| Rocha, MA | 1 |
| Araújo, FA | 1 |
| Moura, SA | 1 |
| Ferreira, MA | 1 |
| Andrade, SP | 1 |
| Udina, E | 2 |
| Ladak, A | 1 |
| Furey, M | 1 |
| Brushart, T | 1 |
| Tyreman, N | 1 |
| Gordon, T | 2 |
| Maher, TM | 1 |
| Wells, AU | 1 |
| Pan, JB | 1 |
| Hou, YH | 1 |
| Zhang, GJ | 1 |
| Chan, KM | 1 |
| Sulaiman, OA | 1 |
| Amirjani, N | 1 |
| Brushart, TM | 1 |
| Lipina, T | 1 |
| Roder, J | 1 |
| Sarmiento, N | 1 |
| Sánchez-Bernal, C | 1 |
| Pérez, N | 1 |
| Sardina, JL | 1 |
| Mangas, A | 1 |
| Calvo, JJ | 1 |
| Sánchez-Yagüe, J | 1 |
| Horn, KP | 1 |
| Silver, J | 1 |
| McCann, FE | 1 |
| Palfreeman, AC | 1 |
| Andrews, M | 1 |
| Perocheau, DP | 1 |
| Inglis, JJ | 1 |
| Schafer, P | 1 |
| Feldmann, M | 1 |
| Williams, RO | 2 |
| Brennan, FM | 1 |
| Bretzner, F | 1 |
| Plemel, JR | 1 |
| Richter, M | 1 |
| Roskams, AJ | 1 |
| Tetzlaff, W | 1 |
| Shih, CH | 1 |
| Lin, LH | 1 |
| Lai, YH | 1 |
| Lai, CY | 1 |
| Han, CY | 2 |
| Chen, CM | 3 |
| Ko, WC | 2 |
| Lin, HB | 2 |
| Huang, Y | 1 |
| de Lima, FM | 1 |
| Moreira, LM | 1 |
| Villaverde, AB | 1 |
| Albertini, R | 1 |
| Castro-Faria-Neto, HC | 1 |
| Aimbire, F | 1 |
| Mironov, SL | 1 |
| Skorova, EY | 1 |
| Kügler, S | 1 |
| Zhuo, YY | 1 |
| Zhou, H | 2 |
| Yang, YL | 1 |
| Hsu, HT | 1 |
| Wang, KH | 1 |
| Homer, L | 1 |
| Launay, E | 1 |
| Joram, N | 1 |
| Jacqueline, C | 1 |
| Jarreau, PH | 1 |
| Caillon, J | 1 |
| Moyon, T | 1 |
| Branger, B | 1 |
| Potel, G | 1 |
| Roze, JC | 1 |
| Méhats, C | 1 |
| Gras-Leguen, C | 1 |
| Anzilotti, S | 1 |
| Dato, C | 1 |
| Leuti, A | 1 |
| Colucci D'Amato, L | 1 |
| Perrone, L | 1 |
| Melone, MA | 1 |
| Atkins, CM | 1 |
| Kang, Y | 1 |
| Furones, C | 1 |
| Truettner, JS | 1 |
| Alonso, OF | 1 |
| Dietrich, WD | 1 |
| Wen, RT | 1 |
| Zhang, M | 1 |
| Qin, WJ | 1 |
| Liu, Q | 1 |
| Wang, WP | 1 |
| Lawrence, AJ | 1 |
| Liang, JH | 1 |
| Wiescholleck, V | 1 |
| Manahan-Vaughan, D | 1 |
| Costa, LM | 1 |
| Pereira, JE | 1 |
| Filipe, VM | 1 |
| Magalhães, LG | 1 |
| Couto, PA | 1 |
| Gonzalo-Orden, JM | 1 |
| Raimondo, S | 1 |
| Geuna, S | 1 |
| Maurício, AC | 1 |
| Nikulina, E | 1 |
| Filbin, MT | 1 |
| Varejão, AS | 1 |
| Schütte, H | 1 |
| Schell, A | 1 |
| Schäfer, C | 1 |
| Ghofrani, A | 1 |
| Theo Schermuly, R | 1 |
| Seeger, W | 1 |
| Grimminger, F | 1 |
| Devillier, P | 1 |
| Itoh, T | 1 |
| Abe, K | 1 |
| Tokumura, M | 1 |
| Horiuchi, M | 1 |
| Inoue, O | 1 |
| Ibii, N | 1 |
| Hamamoto, M | 2 |
| Suga, M | 2 |
| Nakatani, T | 2 |
| Takahashi, Y | 2 |
| Inamori, S | 2 |
| Yagihara, T | 2 |
| Kitamura, S | 2 |
| Alarcón, JM | 1 |
| Malleret, G | 1 |
| Touzani, K | 1 |
| Vronskaya, S | 1 |
| Ishii, S | 1 |
| Kandel, ER | 1 |
| Barco, A | 1 |
| Lee, HT | 1 |
| Chang, YC | 2 |
| Wang, LY | 1 |
| Wang, ST | 1 |
| Huang, CC | 2 |
| Ho, CJ | 1 |
| Maxwell, CR | 1 |
| Siegel, SJ | 1 |
| Gong, B | 1 |
| Vitolo, OV | 1 |
| Trinchese, F | 1 |
| Liu, S | 1 |
| Shelanski, M | 1 |
| Arancio, O | 1 |
| Ariga, M | 1 |
| Neitzert, B | 1 |
| Nakae, S | 1 |
| Mottin, G | 1 |
| Bertrand, C | 1 |
| Jin, SL | 1 |
| Conti, M | 1 |
| Ahloulay, M | 1 |
| Bankir, L | 1 |
| Lugnier, C | 1 |
| Le Bec, A | 1 |
| Poirel, O | 1 |
| Moreau, R | 1 |
| Lebrec, D | 1 |
| Davis, JA | 1 |
| Gould, TJ | 1 |
| Sánchez, AJ | 1 |
| Puerta, C | 1 |
| Ballester, S | 1 |
| González, P | 1 |
| Arriaga, A | 1 |
| García-Merino, A | 2 |
| Comery, TA | 1 |
| Martone, RL | 1 |
| Aschmies, S | 1 |
| Atchison, KP | 1 |
| Diamantidis, G | 1 |
| Gong, X | 1 |
| Kreft, AF | 1 |
| Pangalos, MN | 1 |
| Sonnenberg-Reines, J | 1 |
| Jacobsen, JS | 1 |
| Marquis, KL | 1 |
| Cabranes, A | 1 |
| Venderova, K | 1 |
| de Lago, E | 1 |
| Fezza, F | 1 |
| Sánchez, A | 1 |
| Mestre, L | 1 |
| Valenti, M | 1 |
| Ramos, JA | 1 |
| Di Marzo, V | 1 |
| Fernández-Ruiz, J | 1 |
| Videla, S | 1 |
| Vilaseca, J | 1 |
| Medina, C | 1 |
| Mourelle, M | 1 |
| Guarner, F | 1 |
| Salas, A | 1 |
| Malagelada, JR | 1 |
| Wollin, L | 1 |
| Bundschuh, DS | 1 |
| Wohlsen, A | 1 |
| Marx, D | 1 |
| Beume, R | 1 |
| Tsukumo, Y | 1 |
| Takashima, Y | 1 |
| Costa, DA | 1 |
| Cracchiolo, JR | 1 |
| Bachstetter, AD | 1 |
| Hughes, TF | 1 |
| Bales, KR | 1 |
| Paul, SM | 1 |
| Mervis, RF | 1 |
| Arendash, GW | 1 |
| Potter, H | 1 |
| Xiang, A | 1 |
| Kanematsu, M | 1 |
| Mitamura, M | 1 |
| Kikkawa, H | 1 |
| Asano, S | 1 |
| Kinoshita, M | 1 |
| Baughman, KW | 1 |
| Basso, DM | 1 |
| Strittmatter, SM | 1 |
| Sohara, E | 1 |
| Rai, T | 1 |
| Yang, SS | 1 |
| Uchida, K | 1 |
| Nitta, K | 1 |
| Horita, S | 1 |
| Ohno, M | 1 |
| Harada, A | 1 |
| Sasaki, S | 1 |
| Uchida, S | 1 |
| Nejman-Gryz, P | 1 |
| Grubek-Jaworska, H | 1 |
| Glapińiski, J | 1 |
| Chazan, R | 1 |
| DeMarch, Z | 2 |
| Martorana, A | 1 |
| Siuciak, JA | 1 |
| Chapin, DS | 1 |
| McCarthy, SA | 1 |
| Martin, AN | 1 |
| de Visser, YP | 1 |
| Walther, FJ | 1 |
| Laghmani, EH | 1 |
| van Wijngaarden, S | 1 |
| Nieuwland, K | 1 |
| Wagenaar, GT | 1 |
| De Franceschi, L | 1 |
| Platt, OS | 1 |
| Malpeli, G | 1 |
| Janin, A | 1 |
| Scarpa, A | 1 |
| Leboeuf, C | 1 |
| Beuzard, Y | 1 |
| Payen, E | 1 |
| Brugnara, C | 1 |
| Yang, L | 1 |
| Calingasan, NY | 1 |
| Lorenzo, BJ | 1 |
| Beal, MF | 1 |
| Hung, PL | 1 |
| Huang, HM | 1 |
| Whitaker, CM | 1 |
| Beaumont, E | 1 |
| Wells, MJ | 1 |
| Magnuson, DS | 1 |
| Hetman, M | 1 |
| Onifer, SM | 1 |
| Howell, RE | 1 |
| Jenkins, LP | 1 |
| Howell, DE | 1 |
| Badger, AM | 1 |
| Olivera, DL | 1 |
| Esser, KM | 1 |
| Elwood, W | 1 |
| Sun, J | 1 |
| Barnes, PJ | 1 |
| Giembycz, MA | 1 |
| Chung, KF | 1 |
| Kato, H | 1 |
| Araki, T | 1 |
| Itoyama, Y | 1 |
| Kogure, K | 1 |
| Santing, RE | 1 |
| Olymulder, CG | 1 |
| Van der Molen, K | 1 |
| Meurs, H | 1 |
| Zaagsma, J | 1 |
| Cortijo, J | 1 |
| Bou, J | 1 |
| Beleta, J | 1 |
| Cardelús, I | 1 |
| Llenas, J | 1 |
| Morcillo, E | 1 |
| Gristwood, RW | 1 |
| Klemm, P | 1 |
| Harris, HJ | 1 |
| Perretti, M | 1 |
| Holbrook, M | 2 |
| Gozzard, N | 2 |
| James, T | 2 |
| Higgs, G | 2 |
| Hughes, B | 2 |
| Howat, D | 1 |
| Lisle, H | 1 |
| Blease, K | 1 |
| Hughes, P | 1 |
| Kingaby, R | 1 |
| Warrellow, G | 1 |
| Alexander, R | 1 |
| Head, J | 1 |
| Boyd, E | 1 |
| Eaton, M | 1 |
| Perry, M | 1 |
| Wales, M | 1 |
| Smith, B | 1 |
| Owens, R | 1 |
| Catterall, C | 1 |
| Lumb, S | 1 |
| Russell, A | 1 |
| Allen, R | 1 |
| Merriman, M | 1 |
| Bloxham, D | 1 |
| Miotla, JM | 1 |
| Hellewell, PG | 1 |
| Bleiweis, MS | 1 |
| Jones, DR | 1 |
| Hoffmann, SC | 1 |
| Becker, RM | 1 |
| Egan, TM | 1 |
| Sullivan, GW | 1 |
| Linden, J | 1 |
| Buster, BL | 1 |
| Scheld, WM | 1 |
| Tam, FW | 1 |
| Smith, J | 1 |
| Agarwal, S | 1 |
| Karkar, AM | 1 |
| Morel, D | 1 |
| Thompson, EM | 1 |
| Pusey, CD | 1 |
| Akuta, K | 1 |
| Kawasaki, H | 1 |
| Ohmori, K | 1 |
| 't Hart, BA | 1 |
| van Meurs, M | 1 |
| Brok, HP | 1 |
| Massacesi, L | 1 |
| Bauer, J | 1 |
| Boon, L | 1 |
| Bontrop, RE | 1 |
| Laman, JD | 1 |
| Hammerbeck, DM | 1 |
| McGurran, SM | 1 |
| Radziszewski, PL | 1 |
| Egging, EA | 1 |
| Johnson, DD | 1 |
| Hupperts, AM | 1 |
| Gullikson, GW | 1 |
| Francischi, JN | 1 |
| Yokoro, CM | 1 |
| Poole, S | 2 |
| Tafuri, WL | 1 |
| Cunha, FQ | 1 |
| Beshay, E | 1 |
| Croze, F | 1 |
| Prud'homme, GJ | 1 |
| Spond, J | 1 |
| Chapman, R | 1 |
| Fine, J | 1 |
| Jones, H | 1 |
| Kreutner, W | 1 |
| Kung, TT | 1 |
| Minnicozzi, M | 1 |
| Souza, DG | 1 |
| Cassali, GD | 1 |
| Overstreet, DH | 1 |
| Double, K | 1 |
| Schiller, GD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis[NCT03529955] | Phase 2 | 8 participants (Actual) | Interventional | 2018-06-12 | Completed | ||
| Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients[NCT02489877] | 84 participants (Anticipated) | Observational | 2015-07-31 | Not yet recruiting | |||
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"MMT-8 (Manual Muscle Testing-8) score is a validated tool to assess muscle strength. Calculate the mean change in MMT-8 score at 3 and 6 month(s) compared to baseline in patients with muscle disease.~Units: Units on a scale. Scale goes from 0-150. 150 is perfect strength." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
| Intervention | score on a scale (Mean) |
|---|---|
| MMT-8 Score at 3 Months | 143.3 |
| MMT-8 Score at 6 Months | 144.5 |
"Dermatology Life Quality Index (DLQI) is a validated tool to measure quality of life in patients with skin disease. Complete response is defined by a DLQI of zero at 3, and 6 months. Partial response is defined by a decrease of DLQI of at least 5 points at 3, and 6 months compared to baseline. Calculation is performed as the DLQI at 3, and 6 months minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~Units : Units on a scale from 0-30, higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
| Intervention | score on a scale (Mean) |
|---|---|
| DLQI Score at 3 Months | 6.3 |
| DLQI Score at 6 Months | 4.2 |
"The durability of response will be measured using the CDASI activity score at 6 months minus CDASI activity score at 3 months. Complete response durability is defined as zero or minus difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Partial response durability is defined as >4 points difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 6 months compared to data collected at 3 months
| Intervention | score on a scale (Mean) |
|---|---|
| CDASI Score at 3 Months | 16.9 |
| CDASI Score at 6 Months | 14 |
"Cutaneous dermatomyositis disease area and severity index (CDASI) activity score is a validated tool to measure skin disease activity in dermatomyositis. The overall response rate (ORR) includes partial and complete responses. Complete response is defined by a CDASI activity score of zero. Partial response is defined by a decrease of CDASI activity score of at least 4 points. Calculation is performed as the CDASI activity score at 3 month(s) minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Dermatomyositis Patients With Refractory Cutaneous Disease | 7 |
"The proportion of participants experiencing adverse events and serious adverse events was measured over 7 months period (6 months during the study and 1 month follow up) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.~Grade refers to severity of the AE. The CTCAE displays Grades 1 to 5 with unique clinical descriptions of severity for each AE:~Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental Activity of Daily Living (ADL) Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated Grade 5 Death related to AE All adverse events subjects experienced were grade 1 or 2 which is mild to moderate in severity." (NCT03529955)
Timeframe: 7 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Headache Grade 1-2 | Nausea Grade 1-2 | Diarrhea Grade 1-2 | Herpes Zoster Grade 1-2 | Influenza Grade 1-2 | Pneumonia Grade 1-2 | Acute sinusitis Grade 1-2 | Hypertension Grade 1-2 | Ocular pressure Grade 1-2 | |
| Dermatomyositis Patients With Refractory Cutaneous Disease | 7 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 1 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in gene expression profiling and immunohistochemistry stain. Gene expression profiling will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
| Intervention | Change (Number) | |
|---|---|---|
| Down regulated genes | Up regulated genes | |
| Skin Biopsy at 3 Months Into Apremilast Therapy for Gene Expression Profiling | 123 | 72 |
| Skin Biopsy at Baseline for Gene Expression Profiling | 0 | 0 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in immunohistochemistry stain. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
| Intervention | Percentage of positive cell detection (Mean) | |
|---|---|---|
| STAT1 | STAT3 | |
| Skin Biopsy at 3 Months Into Apremilast Therapy for IHC | 50.1 | 17.4 |
| Skin Biopsy at Baseline for IHC | 96.2 | 44.3 |
4 reviews available for rolipram and Disease Models, Animal
| Article | Year |
|---|---|
Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19?
Topics: Acetates; Angiotensin I; Animals; Annexin A1; Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Trea | 2020 |
Accelerating axon growth to overcome limitations in functional recovery after peripheral nerve injury.
Topics: Animals; Cyclic AMP; Disease Models, Animal; Electric Stimulation Therapy; Growth Cones; Humans; Ner | 2009 |
[Physiopathology of COPD: choosing the right therapeutic targets].
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Animals; Bacterial Infections; Bronchodilator Agents; Carb | 2003 |
Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibody Specificity; Anti | 1998 |
134 other studies available for rolipram and Disease Models, Animal
| Article | Year |
|---|---|
Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Anti-I | 1996 |
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Animals; Anti-Inflammatory Agents; Cyc | 2002 |
Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Mod | 2013 |
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Topics: Animals; Asthma; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Drug Design; | 2017 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Receptors, Serotonin; St | 2019 |
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Cyclic Nucleotide Phosphodiesterases, Type 7 | 2021 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Astrocytes; Biomarkers; Cerebral Hemorrhage; Cycl | 2021 |
Antiallodynic action of phosphodiesterase inhibitors in a mouse model of peripheral nerve injury.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Mice; Neuralgia; Peripheral Nerve Injuries; Phosphodi | 2022 |
Therapeutic efficacy of rolipram delivered by PgP nanocarrier on secondary injury and motor function in a rat TBI model.
Topics: Animals; Apoptosis; Brain Injuries, Traumatic; Disease Models, Animal; Polyethyleneimine; Rats; Reco | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Forebrain-specific conditional calcineurin deficiency induces dentate gyrus immaturity and hyper-dopaminergic signaling in mice.
Topics: Animals; Calcineurin; Cyclic AMP-Dependent Protein Kinases; Dentate Gyrus; Disease Models, Animal; D | 2022 |
Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Fibrosis; Hypercholes | 2023 |
Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apoptosis; Depres | 2023 |
Protective effects of rolipram on endotoxic cardiac dysfunction via inhibition of the inflammatory response in cardiac fibroblasts.
Topics: Animals; Anti-Inflammatory Agents; Cardiomyopathies; Cells, Cultured; Cytokines; Disease Models, Ani | 2020 |
PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Di | 2020 |
Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteremia; Ciprofloxacin; Disease Models, | 2021 |
Pharmacological rescue in patient iPSC and mouse models with a rare DISC1 mutation.
Topics: Animals; Behavior, Animal; Cerebral Cortex; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Mo | 2021 |
The antiepileptogenic effect of low-frequency stimulation on perforant path kindling involves changes in regulators of G-protein signaling in rat.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Biophysics; Disease Models, Animal; Electric S | 2017 |
Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cyclic AMP; Cyclic AMP Resp | 2017 |
Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation.
Topics: Alcohol-Related Disorders; Animals; Astrocytes; Brain; Cells, Cultured; Central Nervous System Depre | 2017 |
Repeated shock stress facilitates basolateral amygdala synaptic plasticity through decreased cAMP-specific phosphodiesterase type IV (PDE4) expression.
Topics: Acoustic Stimulation; Animals; Anxiety; Basolateral Nuclear Complex; Benzazepines; Cyclic Nucleotide | 2018 |
Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat.
Topics: Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepezil; Female; gamma-A | 2018 |
Effect of co-administration of two different phosphodiesterase inhibitors and a β
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; | 2018 |
Rolipram plus Sivelestat inhibits bone marrow-derived leukocytic lung recruitment after cardiopulmonary bypass in a primate model.
Topics: Animals; Bone Marrow Cells; Cardiopulmonary Bypass; Chemotaxis, Leukocyte; Disease Models, Animal; G | 2019 |
Effects of combining methylprednisolone with rolipram on functional recovery in adult rats following spinal cord injury.
Topics: Animals; Axons; Disease Models, Animal; Female; Methylprednisolone; Neurons; Neuroprotective Agents; | 2013 |
The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Brain Injuries; Cytokines; Disease Models, Animal; Enceph | 2013 |
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cilostazol; Disease Models, Animal; Drug Interaction | 2013 |
Rolipram improves renal perfusion and function during sepsis in the mouse.
Topics: Acute Kidney Injury; Animals; Blood Flow Velocity; Disease Models, Animal; Glomerular Filtration Rat | 2013 |
Phosphodiesterase 4 inhibition dose dependently stabilizes microvascular barrier functions and microcirculation in a rodent model of polymicrobial sepsis.
Topics: Animals; Coinfection; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium; Hemodyn | 2014 |
Effects of an immunomodulatory therapy and chondroitinase after spinal cord hemisection injury.
Topics: Animals; Bone Density Conservation Agents; Chondroitin ABC Lyase; Clodronic Acid; Combined Modality | 2014 |
Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Blood Platelets; Cyclic AMP-Dependent Prote | 2014 |
Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model.
Topics: Animals; Benzo(a)pyrene; Cadherins; Carcinogenesis; Chemoprevention; Disease Models, Animal; Female; | 2014 |
Analgesic and anti-inflammatory activity of 7-substituted purine-2,6-diones.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Disease Models, Animal; Edema; Formaldeh | 2014 |
The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Topics: Aminopyridines; Animals; Benzamides; Capillary Permeability; Chemokines; Cyclic Nucleotide Phosphodi | 2015 |
Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Cyclic Nucleotide Phosphodiesterases, Type 4; Depr | 2015 |
Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
Topics: Animals; Body Weight; Corticosterone; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cycli | 2015 |
Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
Topics: Adrenergic alpha-2 Receptor Agonists; Aminopyridines; Animals; Antihypertensive Agents; Benzamides; | 2015 |
Identification and Characterization of Baicalin as a Phosphodiesterase 4 Inhibitor.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Fla | 2016 |
Effects of lisdexamfetamine in a rat model of binge-eating.
Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Mo | 2015 |
Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.
Topics: Animals; Behavior, Animal; Brain; Cognition; Cognition Disorders; Cyclic AMP; Cyclic AMP-Dependent P | 2016 |
Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP/AMPK/SIRT1 pathway after stroke in rats.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Brain; Brain Infarction; Cyclic AMP; | 2016 |
Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by Aβ25-35 in rats.
Topics: Amyloid beta-Peptides; Animals; Antioxidants; Avoidance Learning; Cognition; Cognitive Dysfunction; | 2016 |
Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Ethanol; | 2016 |
Cortisol-induced immune suppression by a blockade of lymphocyte egress in traumatic brain injury.
Topics: Animals; Brain Injuries, Traumatic; Caspase 3; Cell Movement; Cytokines; Disease Models, Animal; Enc | 2016 |
Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Cyclic Nucleotide Phosphodiesterases, Type | 2017 |
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Topics: Animals; Bleomycin; Cell Differentiation; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 4; Cy | 2017 |
Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; D | 2008 |
Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats.
Topics: Acute Disease; Animals; Disease Models, Animal; Kidney; Male; Oxidation-Reduction; Phosphodiesterase | 2008 |
Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; C | 2008 |
Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats.
Topics: Age Factors; Aging; Animals; Animals, Newborn; Disease Models, Animal; Dose-Response Relationship, D | 2008 |
Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.
Topics: Animals; Central Nervous System; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, A | 2009 |
Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
Topics: Acetylcysteine; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; Animals, Newborn; | 2009 |
Improved sensorimotor function by rolipram following focal cerebral ischemia in rats.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Motor Activ | 2008 |
The selective inhibition of type IV phosphodiesterase attenuates the severity of the acute pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Anim | 2009 |
Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; CREB-Binding Protein; Disease Models, Animal; Explor | 2009 |
Activity-based therapies to promote forelimb use after a cervical spinal cord injury.
Topics: Animals; Biotin; Cervical Vertebrae; Dextrans; Disease Models, Animal; Environment, Controlled; Exer | 2009 |
Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury.
Topics: Animals; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme-Linked Immun | 2009 |
Pharmacology of a novel, orally active PDE4 inhibitor.
Topics: Animals; Carboxylic Acids; Cell Line, Transformed; Cyclic AMP; Cyclohexanecarboxylic Acids; Disease | 2009 |
Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury.
Topics: Animals; Cervical Vertebrae; Cyclic AMP; Disease Models, Animal; Functional Laterality; Injections, | 2009 |
Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Topics: Administration, Oral; Animals; Azepines; Carboxylic Acids; Cyclohexanecarboxylic Acids; Disease Mode | 2010 |
Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice.
Topics: Administration, Oral; Animals; Chemokine CCL2; Collagen; Disease Models, Animal; Fibrosis; Inflammat | 2009 |
Rolipram-induced elevation of cAMP or chondroitinase ABC breakdown of inhibitory proteoglycans in the extracellular matrix promotes peripheral nerve regeneration.
Topics: Analysis of Variance; Animals; Chondroitin ABC Lyase; Cyclic AMP; Disease Models, Animal; Extracellu | 2010 |
Lost in translation; from animal models of pulmonary fibrosis to human disease.
Topics: Animals; Bleomycin; Cyclic AMP; Cytokines; Disease Models, Animal; Humans; Idiopathic Pulmonary Fibr | 2009 |
Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats.
Topics: Animals; Bleomycin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Mod | 2009 |
A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.
Topics: Amphetamine; Animals; Bupropion; Clozapine; Conditioning, Psychological; Disease Models, Animal; Dop | 2010 |
Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats.
Topics: Animals; Anthracenes; Ceruletide; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease | 2010 |
A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI.
Topics: Analysis of Variance; Animals; Axons; Brain Stem; Clodronic Acid; Contusions; Disease Models, Animal | 2011 |
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; Disease Models, Animal; Do | 2010 |
Combination of olfactory ensheathing cells with local versus systemic cAMP treatment after a cervical rubrospinal tract injury.
Topics: Animals; Axons; Cell Transplantation; Cyclic AMP; Disease Models, Animal; Glial Fibrillary Acidic Pr | 2010 |
Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects.
Topics: Anesthesia; Animals; Binding Sites; Binding, Competitive; Brain; Cell Membrane; Cyclic Nucleotide Ph | 2010 |
Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Cyclic AMP; Cyclic AMP Respon | 2010 |
Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome.
Topics: Animals; Base Sequence; Cyclic AMP; Disease Models, Animal; DNA Primers; Lipopolysaccharides; Low-Le | 2011 |
Epac-mediated cAMP-signalling in the mouse model of Rett Syndrome.
Topics: Animals; Biological Clocks; Brefeldin A; Cyclic AMP; Disease Models, Animal; Female; Guanine Nucleot | 2011 |
The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats.
Topics: Amyloid beta-Peptides; Animals; Apoptosis; Avoidance Learning; bcl-2-Associated X Protein; Cognition | 2012 |
Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.
Topics: Animals; Asthma; Binding Sites; Blood Cell Count; Bronchial Hyperreactivity; Bronchoalveolar Lavage | 2011 |
Antenatal phosphodiesterase 4 inhibition restores postnatal growth and pulmonary development in a model of chorioamnionitis in rabbits.
Topics: Animals; Chorioamnionitis; Disease Models, Animal; Elastic Tissue; Female; Lung; Lung Volume Measure | 2012 |
Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition.
Topics: Animals; Disease Models, Animal; Huntington Disease; Male; MAP Kinase Signaling System; Mice; Mice, | 2012 |
Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.
Topics: Animals; Brain Injuries; Cerebral Hemorrhage; Cerebrovascular Circulation; Disease Models, Animal; E | 2012 |
The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Disease Models, Animal; Dose-Response Rel | 2012 |
PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis.
Topics: Animals; Antipsychotic Agents; Cyclic AMP; Disease Models, Animal; Dizocilpine Maleate; Dose-Respons | 2012 |
Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Female; Infusion Pumps, Implantable; | 2013 |
Subthreshold doses of nebulized prostacyclin and rolipram synergistaically protect against lung ischemia-reperfusion.
Topics: Animals; Capillary Permeability; Cyclic AMP; Disease Models, Animal; Drug Synergism; Epoprostenol; F | 2003 |
Different regulation of adenylyl cyclase and rolipram-sensitive phosphodiesterase activity on the frontal cortex and hippocampus in learned helplessness rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Animals; Corticosterone; Cyclic AMP; Cyclic | 2003 |
Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiopulmonary Bypass; CD11b Antigen; Cyclic Nucleoti | 2004 |
Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration.
Topics: Acetylation; Analysis of Variance; Animals; Blotting, Western; Brain-Derived Neurotrophic Factor; Ce | 2004 |
cAMP response element-binding protein activation in ligation preconditioning in neonatal brain.
Topics: Analysis of Variance; Animals; Animals, Newborn; Autoradiography; Behavior, Animal; Blotting, Wester | 2004 |
Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications.
Topics: Amphetamine; Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Evoke | 2004 |
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cognition; Cyclic AMP Response Element-B | 2004 |
Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cell Adhesion; Chemokines; Chemotaxis, Leukocyte; Cycl | 2004 |
Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites.
Topics: Analysis of Variance; Animals; Ascites; Cyclic AMP; Disease Models, Animal; Glomerular Filtration Ra | 2005 |
Rolipram attenuates MK-801-induced deficits in latent inhibition.
Topics: Animals; Cyclic AMP; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; | 2005 |
Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis.
Topics: Animals; Cell Movement; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2005 |
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-P | 2005 |
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arachidonic Acids; Basal Ganglia; Brain; Cannabinoid R | 2005 |
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Chronic Disease; Colitis; Colon; Cyclic Nucleotide Pho | 2006 |
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Aminopyridines; Animals; Benzamides; Bron | 2006 |
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Inflammatory Agents; Cell C | 2006 |
Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; | 2007 |
Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Early Diagnosis; | 2006 |
Delayed Nogo receptor therapy improves recovery from spinal cord contusion.
Topics: Animals; Axons; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fem | 2006 |
Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aquaporin 2; Cyclic Nucleotide Phosphodiesterases, Typ | 2006 |
Suppressive effect of phosphodiesterase type 4 inhibition on systemic inflammatory responses after cardiopulmonary bypass.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiopulmonary Bypass; CD11b Antigen; Cyclic Nucleoti | 2006 |
[Effect of phosphodiestrase 4 inhibitor (rolipram) on experimental allergic asthma-guinea pig model].
Topics: Administration, Inhalation; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar L | 2006 |
Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
Topics: Animals; Cell Survival; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models | 2007 |
Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, An | 2007 |
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Topics: Animals; Animals, Newborn; Benzamides; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Gene Ex | 2008 |
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; Mice; Mice, | 2008 |
Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats.
Topics: Action Potentials; Animals; Cervical Vertebrae; Diaphragm; Disease Models, Animal; Electromyography; | 2008 |
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2008 |
Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Dise | 2008 |
Rolipram, a phosphodiesterase type IV inhibitor, exacerbates periventricular white matter lesions in rat pups.
Topics: Animals; Animals, Newborn; Astrocytes; Brain; Cell Proliferation; Cerebral Ventricles; Cyclic AMP Re | 2008 |
Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury.
Topics: Animals; Apoptosis; CD11b Antigen; Cell Survival; Cervical Vertebrae; Cyclic AMP; Cyclic Nucleotide | 2008 |
Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs.
Topics: Aerosols; Aminophylline; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Dexamethas | 1995 |
Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, | 1994 |
Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats.
Topics: Administration, Inhalation; Aerosols; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-S | 1995 |
Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Gerbillinae; Hippocampus; Injecti | 1995 |
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Analysis of Variance; Animals; Asth | 1995 |
Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Animals; Asthma; Bronchodilator Agents; Cyclic Nuc | 1993 |
Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dexametha | 1995 |
Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
Topics: Analysis of Variance; Animals; Benzamides; Bronchial Hyperreactivity; Bronchoconstriction; Carbachol | 1996 |
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Airway Resistance; Analysis of Variance; Animals; Asthma; Benza | 1996 |
Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Capillary Permeability; Cyclic Nucleotide Phosphodiest | 1998 |
Reduced ischemia-reperfusion injury with rolipram in rat cadaver lung donors: effect of cyclic adenosine monophosphate.
Topics: Adenine Nucleotides; Animals; Capillary Permeability; Chromatography, High Pressure Liquid; Cyclic A | 1999 |
Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram.
Topics: Adenosine; Animals; Blood-Brain Barrier; Cell Adhesion; Cyclic AMP; Disease Models, Animal; Drug Syn | 1999 |
Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis.
Topics: Animals; Antibodies; Basement Membrane; Disease Models, Animal; Glomerulonephritis; Kidney; Kidney G | 2000 |
The inhaled administration of KF19514, a phosphodiesterase 4 and 1 inhibitor, prevents antigen-induced lung inflammation in guinea pigs.
Topics: Acetylcholine; Administration, Inhalation; Airway Resistance; Aminophylline; Animals; Asthma; Bronch | 2000 |
A new primate model for multiple sclerosis in the common marmoset.
Topics: Acute Disease; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Callithrix; CD40 Antigens; Cebi | 2000 |
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Androstadienes; Animals; Asthma; Beclomethasone; Benzamides; Bu | 2000 |
Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Exper | 2000 |
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Autoimmune Diseases; Bucladesine; Cells, Cultured; | 2001 |
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Topics: Adrenalectomy; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Humans; Inflammation; I | 2001 |
Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Capillary Permeability; Cyclic Nucleotide Phosphodiest | 2001 |
Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain.
Topics: Albuterol; Animals; Antidepressive Agents; Avoidance Learning; Body Temperature; Brain; Depressive D | 1989 |